IL1RL2 and psoriasis vulgaris: The pro-inflammatory molecules, IL-36α, IL-36β and IL-36γ are significantly upregulated in lesional skin of Psoriasis vulgaris (PsV) and are blocked at the receptor level by the IL-36 Receptor antagonist (IL-36Ra) [13–16].